Hypertension Subtype Defined by the 2017 ACC/AHA Blood Pressure Guidelines and Risk of Cardiovascular Disease: A Large Prospective Cohort Study

Fu-Rong Li1[1*], Xian-Bo Wu[2#]

[1] Department of Epidemiology, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, Guangzhou, Guangdong, China

Correspondence to

Xian-Bo Wu; Department of Epidemiology, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, Guangzhou, Guangdong, China; E-mail: wuxb1010@smu.edu.cn

Abstract

Background The 2017 American College of Cardiology/American Heart Association (ACC/ AHA) blood pressure (BP) guideline lowered the hypertension threshold from a systolic blood pressure/diastolic blood pressure level of ≥140/90 mm Hg to ≥130/80 mm Hg. The significance of hypertension subtype under the new definition has not been fully explored.

Objective To examine the associations of isolated systolic hypertension (ISH) and isolated diastolic hypertension (IDH) by the 2017 ACC/AHA guidelines with risk of cardiovascular disease (CVD) among the UK population.

Design Prospective population-based cohort study

Setting UK Biobank

Participants and Methods: We included 470,625 participants who were free of CVD at baseline and had available data on BP measures. Of these, 13,157 CVD events were recorded (median follow-up 8.1 years), including 6,865 nonfatal myocardial infarctions (MI), 3,415 nonfatal ischemic strokes (ISs), 1,118 nonfatal hemorrhagic strokes (HSs), and 2,971 CVD deaths. Participants were categorized into 5 groups: normal BP, normal high BP, ISH, IDH and systolic and diastolic hypertension (SDH). The associations of each type of hypertension for the risk of CVD were estimated using a Cox proportional hazards regression model with adjustment for potential confounding factors.

Results According to the hypertension threshold of ≥130/80 mm Hg by ACC/AHA guideline, both ISH (HR 1.35, 95% CI 1.24-1.46) and IDH (HR 1.22, 95% CI 1.11-1.36) were significantly associated with higher risk of overall CVD risk, compared with those with normal BP. ISH was predictive of most CVD risk, except for IS; while the excess CVD risk associated with IDH appeared to be driven mainly by MI. We found heterogeneity by sex and age regarding the effects of IDH on overall CVD risk, with the associations stronger in women and younger adults (age < 60 years) and null in men and older adults (age ≥60 years).

Conclusions ISH and IDH by the ACC/AHA BP guideline were both associated with increased risk of CVD, highlighting the justification to lower the criteria of

hypertension definition in the UK. Further research is needed to identify participants with IDH who are at especially greater risk for developing CVD.

Introduction

Hypertension can be diagnosed based on singular and combined elevated systolic blood pressure (SBP) and diastolic blood pressure (DBP). People who fulfill only the SBP or only the DBP hypertension criteria are categorized as having isolated systolic hypertension (ISH) or isolated diastolic hypertension (IDH), respectively.

In 2017, the American College of Cardiology (ACC)/American Heart Association (AHA) lowered the hypertension criterion from an SBP/DBP level of ≥ 140/90 mm Hg to a threshold of ≥ 130/80 mm Hg [1]. Since the release of the new guideline, a number of studies have explored the change in prevalent hypertension in different populations [2-5] or cardiovascular disease (CVD) risk associated with the newly defined hypertension BP stratum (130–139/80–89 mm Hg) [6, 7]. To date, however, only a handful of studies have focused on the impact of the ACC/AHA guidelines on CVD risk associated with hypertension subtypes (e.g., ISH, IDH), and the results are somewhat conflicting. A recent study of multiple cohorts of US adults reported that IDH was not linked to an increased risk of CVD by either hypertension definition (≥140/90 mm Hg or ≥130/80 mm Hg). In contrast, a study of the US outpatient population reported that both systolic and diastolic hypertension independently predicted CVD events [8], regardless of the definition of hypertension.

Indeed, evidence regarding the CVD predictive value of the redefined hypertension subtype was limited, and the conclusions remained unclear. Of note is that this uncertainty is further strengthened by the conflict between the American guidelines and European guidelines. Due to the lack of robust evidence, the 2018 European Society of Hypertension (ESH)/European Society of Cardiology (ESC) Guideline maintained the hypertension definition as BP ≥ 140/90 mm Hg [9]. Similarly, the National Institute of Clinical Excellence (NICE) in the UK has also chosen to maintain the BP threshold of ≥ 140/90 mm Hg for hypertension [10]. Therefore, it is unclear whether the recommendation of the ACC/AHA guideline should be applied to populations in the UK.

To fill the gap in the previous research, we used data from the UK Biobank to explore the associations of hypertension subtype with the risk of CVD, using the BP

threshold defined by the 2017 ACC/AHA guidelines. As there was limited evidence regarding the distribution and CVD prognostic significance of the redefined hypertension subtype in the UK population, our findings provide new insight into hypertension management in the UK.

Methods

Study Population

In total, 502,507 participants (aged 40–69 years) were recruited to the UK Biobank study between 2006 and 2010 from the general population of the UK. Participants completed a touch-screen questionnaire and had physical measurements taken and biological samples collected by trained data nurses in 1 of the 22 assessment centers across England, Wales and Scotland. Details of the UK Biobank study have been reported elsewhere [11, 12]. In the present study, we excluded 1,243 individuals with missing values for SBP or DBP, 29,329 individuals with prevalent CVD events (angina, myocardial infarction (MI) and stroke) at baseline and 1,240 individuals who were lost to follow-up. The final sample for analysis included 470,625 participants.

The UK Biobank has ethical approval from the Northwest Multi-Center Research Ethics Committee, and written informed consent was obtained from all participants.

Assessment of Blood Pressure

BP measurements were measured twice after the participant had been at rest for at least 5 minutes in the seated position by using a digital BP monitor (Omron HEM-7015IT; OMRON Healthcare Europe B.V., Hoofddorp, Netherlands) with a suitably sized cuff. Mean SBP and DBP values were calculated from 2 automated (n=439,829) or 2 manual (n=30,796) BP measurements.

Assessment of the Outcomes

The primary outcome for this study was composite CVD outcome, which was defined as a composite of nonfatal MI, nonfatal ischemic stroke (IS), nonfatal hemorrhagic stroke (HS) and CVD death. The secondary outcomes were the above individual CVD

events. Information on CVD events and the timing of events were identified by linking to the Scottish Morbidity Records for participants from Scotland and health episode statistics for participants from England and Wales. The date and cause of death were identified by linking to death registries of the National Health Service (NHS) Information Centre for participants from England and Wales and the NHS Central Register Scotland for participants from Scotland [12]. At the time of analysis, hospital admission data were available up to March 29, 2017, and mortality data were available up to February 12, 2018 for England and Wales and August 12, 2016 for Scotland; therefore, these dates were used as the end of follow-up. Follow-up time was calculated from the date of baseline assessment to the date of diagnosis of the event, death, or the end of follow-up, whichever occurred first.

The International Classification of Diseases, tenth revision (ICD-10) codes were included in death records, while ICD-10 and International Classification of Diseases, ninth revision (ICD-9) codes were used in medical records. MI was defined as ICD-9 codes 410-414 and ICD-10 codes I20-I25. IS was defined as ICD-9 codes 433-434 and ICD-10 code I63; and HS was defined as ICD-9 codes 430-432 and ICD-10 codes I60-I62 [13]. CVD death was defined as ICD-10 codes I00-I99.

Assessment of Covariates

We used the baseline touch screen questionnaire to include potential confounders: sociodemographic information (age, sex, ethnicity); area-based socioeconomic status (Townsend score); lifestyle (smoking, drinking, dietary habits); and self-reported medical conditions (medications to treat high cholesterol and hypertension; history of diabetes and long-standing illness). Biomarkers were also used for analysis. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m^2). Dietary habits were assessed through a food frequency questionnaire. The ion selective electrode method was used to measure sodium levels in stored urine samples [14]. Serum cystatin C was measured by a latex-enhanced immunoturbidimetric method on a Siemens ADVIA 1800 instrument [15]. The healthy diet score was calculated by using the medians of several dietary factors [13]:

red meat intake less than three times each week; vegetable intake at least four tablespoons each day; fruit intake at least three pieces each day; fish intake at least four times each week; cereal intake at least five bowls each week; and urinary sodium concentration less than 68.3 mmol/L. Each favorable diet factor was assigned a score of 1 point, resulting in a total diet score ranging from 0 to 6. eGFR was calculated by CKD–EPI using serum cystatin C equations as previously reported [16].

Statistical Analysis

Participants were stratified into 5 BP categories: 1) normal (SBP <120 mm Hg and DBP <80 mm Hg), 2) normal high (SBP 120 to 129 mm Hg and DBP <80 mm Hg), 3) ISH (SBP ≥130 mm Hg & DBP <80 mm Hg), 4) IDH (SBP <130 mm Hg & DBP ≥80 mm Hg), and 5) combined isolated systolic blood pressure and diastolic blood pressure (SDH) (SBP ≥130 mm Hg & DBP ≥80 mm Hg). Participants with normal BP were used as the reference. For supplementary analysis, we combined the normal BP group and normal high group, resulting in a new normal BP category as the reference (<130/90 mm Hg). To facilitate comparisons between guidelines, we also divided the sample into 5 categories by using the hypertension threshold (≥140/90 mm Hg) recommended by NICE guidelines.

Multivariable Cox regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between hypertension subtypes and CVD risk. There was no evidence of violation of the proportional hazards assumption based on the tests using Schoenfeld's residuals. Responses of "not known" or "prefer not to answer" to the covariates were considered missing values. Missing values accounted for < 2.5% of all the covariates. Participants with missing values for any of the covariates were assigned to a separate "unknown" category. Two models were used to account for potential confounders. Model 1 included age (continuous) and sex. Model 2 further included ethnicity (White, mixed, Asian or Asian British, black or black British, Chinese, or other ethnic group), Townsend scores (in quintiles), BMI (in quintiles), smoking (never, previous, current), alcohol consumption (daily or almost daily, three or four times a week, once or twice a week,

one to three times a month, special occasions only, never), healthy diet score, hypertensive medication use, cholesterol-lowering medication use, history of diabetes, long-standing illness and eGFR.

For the subgroup analysis, we examined the associations between BP categories and the primary outcome stratified by age (<65 years or ≥65 years) and sex. Several sensitivity analyses were performed to test the robustness of the primary result: 1) additional adjustment for physical activity; 2) additional adjustment for biomarkers, including serum concentration of low-density lipoprotein, high-density lipoprotein and triglyceride; 3) combination of the aforementioned sensitivity analyses; 4) exclusion of those who had CVD events in the first two years of follow-up; 5) exclusion of those with missing variables; 6) exclusion of those taking antihypertensive medications; and 7) additional adjustment for baseline SBP or DBP for IDH or ISH, respectively.

Analyses were conducted using Stata version 14.0 (College Station, Texas). A *P*-value <0.05 was considered indicative of statistical significance.

RESULTS

Baseline Characteristics

This study consisted of 470,625 participants (mean age 57 years), of whom 208,231 (44.3%) were men. The percentages of participants with ISH, IDH, and SDH were 15.9%, 7.5%, and 51.8% under the ACC/AHA guidelines, respectively, and 25.9%, 3.2%, and 21.3% under the NICE guidelines, respectively (Fig. 1).

Baseline characteristics of the study participants by normal BP status and hypertension subtype are presented in Table 1. The mean age of the study participants for ISH was 59.3 years, while those with IDH had a mean age of 52.5 years. Compared to participants with normal BP, those with all other hypertension subtypes had a higher mean SBP, DBP and BMI. Moreover, hypertensive participants were more likely to have lower Townsend scores, have a higher alcohol intake, take hypertensive and cholesterol-lowering medications, and have a history of diabetes or long-term illness, but they were less likely to be current smokers and have a lower

level of eGFR. With the exception of those with ISH, hypertensive participants also tended to have lower healthy diet scores.

Associations between Hypertension Subtypes and Risk of CVD

During a median follow-up of 8.1 years, a total of 13,157 CVD events were recorded, including 6,865 nonfatal MIs, 3,415 nonfatal ischemic strokes, 1,118 nonfatal hemorrhagic strokes, and 2,971 CVD deaths. Using the hypertension cutoff of ≥130/80 mm Hg according to the ACC/AHA guideline, the multivariable-adjusted HRs (95% CI) of overall CVD outcome were 1.08 (0.98-1.18) for high normal BP, 1.35 (1.24-1.46) for ISH, 1.22 (1.11-1.36) for IDH, and 1.51 (1.40-1.62) for SDH, respectively, compared with those with normal BP. Regarding the associations between ISH and individual CVD events, a null association was found for nonfatal IS (HR 1.15, 95% CI 0.98-1.34), whereas significant results were observed for nonfatal MI (HR 1.45, 95% CI 1.29-1.63), nonfatal HS (HR 1.53, 95% CI 1.18-2.00), and CVD mortality (HR 1.23, 95% CI 1.04-1.46). Moreover, for IDH, only the result for nonfatal MI was evident (HR 1.27, 95% CI 1.10-1.47). The results for SDH were consistently significant across all CVD events (Table 2). For the NICE guideline (cutoff of ≥140/90 mm Hg), compared with those with normal BP, all hypertension phenotypes were associated with higher risks of all CVDs, with the exception of CVD mortality, indicating a null association (HR 1.15, 95% CI 0.88-1.49) (Supplemental Table 1).

Subgroup analyses by age showed that the primary results were consistent for the young adults (aged< 60 years), while for older adults (aged ≥ 60 years), the primary results remained similar for ISH and SDH but lost statistical significance for IDH (HR 1.08, 95% CI 0.94-1.28). Notably, we also found that men with IDH were not associated with a higher risk of CVD (HR 1.07, 95% CI 0.94-1.23), whereas the results were evident for all hypertension subtypes among women (Table 3).

Exploratory Analysis and Sensitivity Analysis

Redefining the normal BP group by combining the original normal group and high

normal group did not substantially change the results, except for the link between IDH and CVD death, which turned out to be statistically significant (HR 1.23, 95% CI 1.02-1.48) (Supplemental Table 3). Sensitivity analysis yielded similar results after additional adjustment for physical activity, biomarkers, or combination of the aforementioned analysis. Exclusion of participants with any missing covariates or those taking antihypertensive medications also yielded similar results (Supplemental Table 4). Of note, the significant results remained unchanged after additional adjustment for baseline SBP for IDH or baseline DBP for ISH, regardless of hypertension definition (Supplemental Table 5).

Discussion

The present study evaluated the associations of different subtypes of hypertension, defined by the 2017 ACC/AHA guideline, with the risk of CVD outcomes in a large prospective cohort study of the UK population. We found that the excess overall CVD risks were evident among participants with ISH or IDH compared to their normotensive counterparts. The findings regarding ISH and IDH persisted across a series of sensitivity analyses, even after taking the baseline BP into account. We found heterogeneity by sex and age regarding the effects of IDH on CVD, with the associations being stronger in women and younger adults (age < 60 years) and null in men and older adults (age ≥60 years)

Few prospective studies have assessed the associations between hypertension subtype and CVD risk, especially in the context of the new definition according to the ACC/AHA guidelines. Flint *et al*. examined the impact of outpatient BP on CVD risk among 1.3 million US adults (median age 53 years) and found that both SBP and DBP independently predicted adverse CVD events, regardless of the definition of hypertension (≥140/90 mm Hg or ≥130/80 mm Hg) [8]. Unfortunately, this study did not report the results for isolated hypertensions as simple binary variables. Yano *et al*. reported that among 27,081 younger and middle-aged US adults (mean age, 34 years), all hypertension subtypes, defined by the threshold of ≥140/90 mm Hg, were associated with an increased risk of CVD [17]; similar findings were also reported

from a cohort study of 169,871 Chinese men and women (aged ≥ 40 years) [18]. As most of the hypertension phenotypes were defined by the BP cutoff of ≥140/90 mm Hg in the above studies, their results may not be applicable to the current ACC/AHA guidelines.

Although a few studies have found positive results for IDH under the BP threshold of ≥140/90 mm Hg [17, 18], this was not the case in many previous studies. In fact, while the detrimental effects of ISH and SDH on CVD are without much controversy, the situation is less clear for IDH — the existing evidence regarding this issue is somewhat mixed. For instance, a recent study by McEvoy *et al*. failed to find significant results by either hypertension definition for IDH. In that study, a comprehensive analysis was performed to explore the associations of IDH with the risk of CVD among US adults from several cohort studies (ARIC, NHANES and CLUE II) [19]. The uncertainty in the CVD predictive value of IDH was also reflected by the null associations in other studies [20-23]. The current study showed that by using the threshold of 130/80 mm Hg, ISH was a significant predictor of most CVD events, yet the excess CVD risk associated with IDH appeared to be driven mainly by MI; the associations between IDH and other individual CVD events (IS, HS, CVD death) were not statistically significant. The lack of statistically significant associations of IDH with some of the CVD outcomes calls into question the pathogenicity of IDH.

Differences in biological processes may be responsible for the stronger effects of ISH than IDH on CVD risk [24, 25]. ISH is characterized by higher stroke volume and/or aortic stiffness, and the occurrence of this phenotype is believed to reflect the high BP pressure for multiple organs (e.g., brain, heart, and kidneys) [26, 27], which may result in poorer outcomes. Additionally, ISH is more likely to be the end point of SBP and DBP, both of which would be risk factors for CVD [28]. IDH is a consequence of an increase in arteriolar resistance only [22, 24]; as a result, participants with IDH may bear less vascular burden than those with ISH. In fact, a clear understanding of the pathophysiologic mechanisms underlying different hypertension phenotypes may help establish appropriate treatment recommendations

in clinical practice.

An important finding of this study is that the increased risks of CVD associated with IDH were mainly concentrated in women or those aged <60 years. In general, women differ significantly from men in central arterial pressure and have inappropriately higher vascular loading conditions [29-31]; in addition, the association between arterial stiffness and left ventricular diastolic function appeared to be stronger in women than in men [32], which may collectively explain the sex-specific associations. A study of the UK Biobank also confirmed that BP was more strongly associated with MI in women than in men [33]. Previous studies have found that ISH is most common among elderly individuals, while IDH is more frequent in young and middle-aged persons [34]. As the CVD risk increases by age, the age-specific prevalence of ISH and IDH may result in the differences in the CVD risks associated with these two phenotypes. In summary, these findings may indicate that tailored strategies for hypertension management would be needed based on age and sex.

Strength and Limitations

To the best of our knowledge, this is the first study to verify the validation of different hypertension subtypes according to the ACC/AHA guideline in predicting CVD risk. The strength of the study is that the cohort is large and has a median of 8.1 years of follow-up and 13,157 CVD events, which allow us to perform analyses by subtypes of hypertension and CVD events. A few limitations should also be acknowledged. First, BP measurements were collected only at a single visit, and changes over time would attenuate findings toward the null hypothesis, causing underestimation of the true associations. Second, the potential risk of bias due to “white-coat” effects should also be taken into account, as a patient’s BP measured in a clinic or office may be higher than their ambulatory pressure. Third, the study was based on a sample of the UK population, which limits the generalizability of the findings to other populations.

Conclusions

ISH and IDH according to the ACC/AHA BP guideline were both associated with increased risks of CVD, highlighting the justification to lower the criteria for the hypertension definition in the UK. Further research is needed to identify participants with IDH who are at especially greater risk for developing CVD.

Table 1. Baseline characteristics by normal BP status and hypertension subtype.

Characteristics	Normal	High normal	ISH	IDH	SDH
No. of participants	63,395	53,611	74,634	35,332	243,653
Age, y	52.1±7.8	54.6±8.1	59.3±7.5	52.5±7.6	57.3±7.7
Men	24.7	39.6	41.9	38.4	51.9
SBP, mm Hg	111.5±6.2	124.4±2.8	142.4±11.5	123.7±4.7	151.9±15.7
DBP, mm Hg	69.4±5.8	73.1±4.7	74.3±4.4	83.9±3.8	90.1±7.5
Ethnicity					
White	92.7%	94.3%	95.9%	92.1%	94.3%
Mixed	0.9%	0.7%	0.4%	0.8%	0.5%
Asian or Asian British	2.4%	1.8%	1.4%	2.7%	1.8%
Black or black British	1.6%	1.4%	1.0%	2.3%	1.8%
Chinese	0.6%	0.3%	0.2%	0.5%	0.3%
Other ethnic group	1.3%	1.0%	0.6%	1.3%	0.8%
Townsend score	-1.1±3.2	-1.3±3.1	-1.5±3.0	-1.1±3.2	-1.4±3.0
BMI, kg/m^2	25.0±4.0	25.9±4.1	26.6±4.3	28.0±5.1	28.3±4.8
Smoking					
Never	57.2%	57.0%	54.5%	56.6%	54.9%
Former	29.6%	31.3%	35.4%	30.5%	35.1%
Current	12.8%	11.3%	9.6%	12.4%	9.5%
Alcohol drinking	27.3%	26.7%	25.5%	27.2%	25.3%
Never	9.0%	8.2%	8.5%	8.2%	7.1%
Special occasions only	12.6%	11.7%	12.2%	12.5%	10.6%
One to three times a month	13.4%	11.9%	11.2%	12.1%	10.3%
One or two times a week	27.3%	26.7%	25.5%	27.2%	25.3%
Three or four times a week	22.1%	23.1%	22.5%	22.2%	24.0%
Daily or almost daily	15.4%	18.3%	19.9%	17.7%	22.6%
Healthy diet score	3.0±1.4	3.0±1.4	3.1±1.4	2.8±1.4	2.8±1.4
Hypertensive medication use	2.7%	4.3%	9.7%	7.3%	14.1%
Cholesterol-lowering medication use	6.1%	9.8%	18.1%	9.5%	15.5%
Diabetes	3.3%	4.8%	8.9%	4.8%	6.6%
Long-term illness	25.2%	26.9%	31.7%	29.6%	30.2%
eGFR, ml min^{-1} per 1.73 m^2	94.2±15.2	91.5±15.6	86.4±16.2	92.0±15.8	87.3±15.6

Abbreviation: ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Table 2. Associations of hypertension subtype according to the ACC/AHA definition with risk of CVD.

	Normal	High normal	ISH	IDH	SDH
No. of participants	63,395	53,611	74,634	35,332	243,653
CVD Incidence					
Events	815	970	2,394	682	8,296
Model 1 (HR [95% CI])	1 (reference)	1.07 (0.98-1.18)	1.41 (1.30-1.53)	1.31 (1.19-1.46)	1.56 (1.45-1.68)
Model 2 (HR [95% CI])	1 (reference)	1.08 (0.98-1.18)	1.35 (1.24-1.46)	1.22 (1.11-1.36)	1.51 (1.40-1.62)
MI incidence					
Events	389	514	1,209	352	4,401
Model 1 (HR [95% CI])	1 (reference)	1.18 (1.04-1.35)	1.53 (1.36-1.72)	1.38 (1.20-1.60)	1.72 (1.54-1.91)
Model 2 (HR [95% CI])	1 (reference)	1.18 (1.04-1.35)	1.45 (1.29-1.63)	1.27 (1.10-1.47)	1.64 (1.47-1.82)
IS incidence					
Events	228	247	625	164	2,151
Model 1 (HR [95% CI])	1 (reference)	0.96 (0.80-1.15)	1.21 (1.04-1.41)	1.17 (0.96-1.43)	1.41 (1.23-1.62)
Model 2 (HR [95% CI])	1 (reference)	0.96 (0.81-1.16)	1.15 (0.98-1.34)	1.10 (0.90-1.34)	1.36 (1.18-1.56)
HS incidence					
Events	83	99	212	53	671
Model 1 (HR [95% CI])	1 (reference)	1.22 (0.91-1.64)	1.48 (1.14-1.92)	1.12 (0.79-1.58)	1.58 (1.25-2.00)
Model 2 (HR [95% CI])	1 (reference)	1.27 (0.95-1.70)	1.53 (1.18-2.00)	1.18 (0.84-1.68)	1.71 (1.35-2.18)
CVD mortality					
Events	191	196	615	157	1,812
Model 1 (HR [95% CI])	1 (reference)	0.87 (0.71-1.06)	1.33 (1.13-1.57)	1.26 (1.03-1.56)	1.27 (1.09-1.48)
Model 2 (HR [95% CI])	1 (reference)	0.87 (0.72-1.07)	1.23 (1.04-1.46)	1.15 (0.93-1.42)	1.22 (1.04-1.42)

Abbreviation: HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease; ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Model 1 was adjusted for age and sex.

Model 2 was adjusted for covariates in Model 1 and was additional adjusted for ethnicity, Townsend scores, BMI, smoking status, alcohol consumption, healthy diet score, hypertensive drug use, cholesterol-lowering medication use, history of diabetes, long-standing illness.

Table 3. Subgroup analysis for the primary outcome by hypertension subtype according to the ACC/AHA definition.

	Normal	High normal	ISH	IDH	SDH
Age <60 y					
No. of participants	49,729	35,637	30,341	27,726	131,326
Events	416	402	535	406	3,034
Model 1 (HR [95% CI])					
Model 2 (HR [95% CI])	1 (reference)	1.09 (0.95-1.25)	1.41 (1.24-1.61)	1.32 (1.15-1.52)	1.67 (1.50-1.87)
Age ≥60 y					
No. of participants	13,666	17,974	44,293	7,606	112,327
Events	399	568	1,859	276	5,262
Model 1 (HR [95% CI])					
Model 2 (HR [95% CI])	1 (reference)	1.02 (0.90-1.16)	1.20 (1.08-1.34)	1.08 (0.94-1.28)	1.32 (1.19-1.46)
Men					
No. of participants	15,687	21,210	31,251	13,569	126,514
Events	448	551	1,412	426	5,767
Model 1 (HR [95% CI])					
Model 2 (HR [95% CI])	1 (reference)	0.88 (0.78-1.00)	1.13 (1.02-1.26)	1.07 (0.94-1.23)	1.28 (1.16-1.41)
Women					
No. of participants	47,708	32,401	43,383	21,763	117,139
Events	367	419	982	256	2,529
Model 1 (HR [95% CI])					
Model 2 (HR [95% CI])	1 (reference)	1.32 (1.14-1.52)	1.56 (1.37-1.76)	1.38 (1.17-1.62)	1.75 (1.56-1.96)

Abbreviation: HR, hazard ratio; CI, confidence interval; ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Model 1 was adjusted for age and sex.

Model 2 was adjusted for covariates in Model 1 and was additional adjusted for ethnicity, Townsend scores, BMI, smoking status, alcohol consumption, healthy diet score, hypertensive drug use, cholesterol-lowering medication use, history of diabetes, long-standing illness.

Figure 1. Participants meeting the definitions for hypertension subtypes by different guidelines definition.



Abbreviation: ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Supplemental Table 1. Multivariate-adjusted HRs (95% CIs) for risk of CVD by hypertension subtype according to the NICE definition.

	Normal	High normal	ISH	IDH	SDH
No. of participants	63,395	169,777	121,986	15,234	100,233
CVD Incidence					
Events	815	3,518	4,483	393	3,948
Model 1	1 (reference)	1.18 (1.09-1.27)	1.54 (1.43-1.66)	1.59 (1.41-1.79)	1.77 (1.64-1.91)
Model 2	1 (reference)	1.16 (1.07-1.25)	1.48 (1.37-1.60)	1.44 (1.28-1.63)	1.72 (1.59-1.86)
MI incidence					
Events	389	514	1,209	352	4,401
Model 1	1 (reference)	1.28 (1.15-1.43)	1.70 (1.52-1.90)	1.61 (1.35-1.91)	1.94 (1.74-2.17)
Model 2	1 (reference)	1.25 (1.12-1.40)	1.62 (1.45-1.81)	1.44 (1.21-1.71)	1.87 (1.67-2.09)
IS incidence					
Events	228	856	1,186	103	1,042
Model 1	1 (reference)	1.02 (0.88-1.18)	1.35 (1.17-1.56)	1.56 (1.24-1.97)	1.64 (1.42-1.90)
Model 2	1 (reference)	1.00 (0.86-1.16)	1.29 (1.11-1.49)	1.43 (1.13-1.81)	1.60 (1.37-1.85)
HS incidence					
Events	83	332	373	35	295
Model 1	1 (reference)	1.27 (1.00-1.62)	1.56 (1.22-1.99)	1.66 (1.11-2.46)	1.69 (1.31-2.16)
Model 2	1 (reference)	1.34 (1.05-1.72)	1.66 (1.29-2.13)	1.81 (1.21-2.70)	1.85 (1.44-2.39)
CVD mortality					
Events	191	769	1,066	80	865
Model 1	1 (reference)	1.02 (0.87-1.19)	1.33 (1.13-1.55)	1.32 (1.02-1.72)	1.44 (1.23-1.69)
Model 2	1 (reference)	1.00 (0.85-1.17)	1.24 (1.06-1.46)	1.15 (0.88-1.49)	1.39 (1.18-1.64)

Abbreviation: HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease; ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.
Model 1 was adjusted for age and sex.
Model 2 was adjusted for covariates in Model 1 and was additional adjusted for ethnicity, Townsend scores, BMI, smoking status, alcohol consumption, healthy diet score, hypertensive drug use, cholesterol-lowering medication use, history of diabetes, long-standing illness.

Supplemental Table 2. Associations of hypertension subtype by ACC/AHA definition with risk of CVD.

	Normal*	ISH	IDH	SDH
No. of participants	117,006	74,634	35,332	243,653
CVD Incidence				
Events	1,785	2,394	682	8,296
Multivariable adjusted (HR [95% CI])	1 (reference)	1.29 (1.21-1.37)	1.18 (1.08-1.29)	1.44 (1.37-1.52)
MI incidence				
Events	903	1,209	352	4,401
Multivariable adjusted (HR [95% CI])	1 (reference)	1.32 (1.21-1.44)	1.16 (1.02-1.31)	1.49 (1.38-1.61)
IS incidence				
Events	475	625	164	2,151
Multivariable adjusted (HR [95% CI])	1 (reference)	1.17 (1.03-1.32)	1.12 (0.94-1.34)	1.38 (1.25-1.53)
HS incidence				
Events	182	212	53	671
Multivariable adjusted (HR [95% CI])	1 (reference)	1.35 (1.10-1.66)	1.05 (0.77-1.42)	1.51 (1.27-1.80)
CVD mortality				
Events	387	615	157	1,812
Multivariable adjusted (HR [95% CI])	1 (reference)	1.32 (1.16-1.51)	1.23 (1.02-1.48)	1.31 (1.17-1.47)

*This categorization was defined as BP <130/80 mm Hg.

Abbreviation: HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease; ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Multifactorial adjustments were made for age, sex, ethnicity, Townsend scores, BMI, smoking status, alcohol consumption, healthy diet score, hypertensive drug use, cholesterol-lowering medication use, history of diabetes, long-standing illness.

Supplemental Table 3. Sensitivity analyses of hypertension subtype by ACC/AHA definition and risk of CVD.

	Normal	High normal	ISH	IDH	SDH
Model 2 + PA					
Multivariable adjusted (HR [95% CI])	1 (reference)	1.08 (0.98-1.18)	1.34 (1.24-1.46)	1.22 (1.11-1.36)	1.50 (1.40-1.62)
Model 2 + biomarkers					
Multivariable adjusted (HR [95% CI])	1 (reference)	1.07 (0.98-1.18)	1.34 (1.24-1.46)	1.19 (1.07-1.32)	1.48 (1.37-1.60)
Model 2 + PA and biomarkers					
Multivariable adjusted (HR [95% CI])	1 (reference)	1.07 (0.98-1.18)	1.34 (1.24-1.46)	1.19 (1.07-1.32)	1.48 (1.37-1.59)
Exclusion of missing variables					
Multivariable adjusted (HR [95% CI])	1 (reference)	1.09 (0.99-1.20)	1.35 (1.24-1.47)	1.21 (1.09-1.35)	1.51 (1.40-1.63)
Exclusion of those first 2 year					
Multivariable adjusted (HR [95% CI])	1 (reference)	1.13 (1.02-1.25)	1.39 (1.27-1.52)	1.23 (1.10-1.38)	1.55 (1.43-1.69)
Exclusion of those taking antihypertensive medications					
Multivariable adjusted (HR [95% CI])	1 (reference)	1.10 (1.00-1.21)	1.39 (1.27-1.52)	1.28 (1.15-1.43)	1.62 (1.50-1.76)

Abbreviation: HR, hazard ratio; CI, confidence interval; PA, physical activity; CVD, cardiovascular disease; ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Molder 2 was adjusted for age, sex, ethnicity, Townsend scores, BMI, smoking status, alcohol consumption, healthy diet score, hypertensive drug use, cholesterol-lowering medication use, history of diabetes, long-standing illness.

Supplemental Table 4. Sensitivity analyses of hypertension subtype by ACC/AHA definition and risk of CVD, taking into account the baseline BP.

	Normal	ISH	IDH
ACC/AHA guideline (HR [95% CI])	1.00 (reference)	1.28 (1.17-1.40)	1.34 (1.16-1.55)
NICE guideline (HR [95% CI])	1.00 (reference)	1.41 (1.29-1.54)	1.38 (1.17-1.62)

For IDH, the multivariable adjusted model was further for baseline SBP; whereas for ISH, the multivariable adjusted model was further adjusted for baseline DBP.

Abbreviation: HR, hazard ratio; CI, confidence interval; ISH, isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic diastolic hypertension.

Multifactorial adjustments were made for age, sex, ethnicity, Townsend scores, BMI, smoking status, alcohol consumption, healthy diet score, hypertensive drug use, cholesterol-lowering medication use, history of diabetes, long-standing illness.

References:

1 Whelton PK, Carey RM, Aronow WS, Casey DJ, Collins KJ, Dennison HC, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SJ, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KS, Williamson JD, Wright JJ. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 138: e484-594.

2 Mancia G, Corrao G. Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Italy. Circulation. 2018; 137: 889-90.

3 Wander GS, Ram C. Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: A Perspective From India. Circulation. 2018; 137: 549-50.

4 Wang JG, Liu L. Global Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From China. Circulation. 2018; 137: 546-8.

5 Brunström M, Carlberg B, Lindholm LH. Perspective From Sweden on the Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines. Circulation. 2018; 137: 886-8.

6 Qi Y, Han X, Zhao D, Wang W, Wang M, Sun J, Liu J, Li Y, Gao S, Hao Y, Deng Q, Liu J. Long-Term Cardiovascular Risk Associated With Stage 1 Hypertension Defined by the 2017 ACC/AHA Hypertension Guideline. J Am Coll Cardiol. 2018; 72: 1201-10.

7 Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, Yu HT, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip G. Ideal Blood Pressure in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018; 72: 1233-45.

8 Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, Melles RB, Bhatt DL. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. N Engl J Med. 2019; 381: 243-51.

9 Maniero C, Gupta AK, Lobo MD. Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines in the UK. Eur Heart J. 2019; 40: 2472-5.

10 Boffa RJ, Constanti M, Floyd CN, Wierzbicki AS. Hypertension in adults: summary of updated NICE guidance. BMJ. 2019; 367: l5310.

11 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. Plos Med. 2015; 12: e1001779.

12 Palmer LJ. UK Biobank: bank on it. Lancet. 2007; 369: 1980-2.

13 Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, Heianza Y, Qi L. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019; 365: l1628.

14 Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008; 37: 234-44.

15 Lees JS, Welsh CE, Celis-Morales CA, Mackay D, Lewsey J, Gray SR, Lyall DM, Cleland JG, Gill J, Jhund PS, Pell J, Sattar N, Welsh P, Mark PB. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nat Med.

2019
16 Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367: 20-9.
17 Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, Liu K, Greenland P, Lloyd-Jones DM. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol. 2015; 65: 327-35.
18 Kelly TN, Gu D, Chen J, Huang JF, Chen JC, Duan X, Wu X, Yau CL, Whelton PK, He J. Hypertension subtype and risk of cardiovascular disease in Chinese adults. Circulation. 2008; 118: 1558-66.
19 McEvoy JW, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020; 323: 329.
20 Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation. 2005; 111: 1121-7.
21 Nielsen WB, Lindenstrøm E, Vestbo J, Jensen GB. Is Diastolic Hypertension an Independent Risk Factor for Stroke in the Presence of Normal Systolic Blood Pressure in the Middle-aged and Elderly? Am J Hypertens. 1997; 10: 634-9.
22 Strandberg TE, Salomaa VV, Vanhanen HT, Pitkala K, Miettinen TA. Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens. 2002; 20: 399-404.
23 Hozawa A, Ohkubo T, Nagai K, Kikuya M, Matsubara M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. Arch Intern Med. 2000; 160: 3301-6.
24 Verdecchia P, Angeli F. Natural history of hypertension subtypes. Circulation. 2005; 111: 1094-6.
25 Smulyan H, Safar ME. Systolic blood pressure revisited. J Am Coll Cardiol. 1997; 29: 1407-13.
26 Messerli FH, Frohlich ED, Suarez DH, Reisin E, Dreslinski GR, Dunn FG, Cole FE. Borderline hypertension: relationship between age, hemodynamics and circulating catecholamines. Circulation. 1981; 64: 760-4.
27 Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971; 44: 413-8.
28 Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. Circulation. 1980; 61: 1179-82.
29 Cecelja M, Jiang B, McNeill K, Kato B, Ritter J, Spector T, Chowienczyk P. Increased wave reflection rather than central arterial stiffness is the main determinant of raised pulse pressure in women and relates to mismatch in arterial dimensions: a twin study. J Am Coll Cardiol. 2009; 54: 695-703.
30 Smulyan H, Asmar RG, Rudnicki A, London GM, Safar ME. Comparative effects of aging in men and women on the properties of the arterial tree. J Am Coll Cardiol. 2001; 37: 1374-80.
31 Hayward CS, Kelly RP. Gender-related differences in the central arterial pressure waveform. J Am Coll Cardiol. 1997; 30: 1863-71.
32 Shim CY, Park S, Choi D, Yang WI, Cho IJ, Choi EY, Chung N, Ha JW. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol.

2011; 57: 1226-33.

33 Millett E, Peters S, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018; 363: k4247.

34 Verdecchia P, Angeli F. Natural history of hypertension subtypes. Circulation. 2005; 111: 1094-6.